title: Is it time for everolimus-based combination in castration-resistant prostate cancer?
authors.affiliation: Section of Pharmacology & University Center DIFF - Drug Innovation Forward Future, Department of Molecular & Translational Medicine, University of Brescia, Viale Europa 11, 25124 Brescia, Italy.|Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
authors.forename: Giandomenico
authors.initials: G
authors.lastname: Roviello
authors.affiliation: Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.|Section of Experimental Oncology, Department of Clinical & Experimental Medicine, University of Parma, Via Università, 12, 43121 Parma, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Ravelli
authors.affiliation: Unit of Oncology, Azienda Ospedaliera Treviglio, Treviglio (BG), Italy.
authors.forename: Sandro
authors.initials: S
authors.lastname: Barni
authors.affiliation: Unit of Oncology, Azienda Ospedaliera Treviglio, Treviglio (BG), Italy.
authors.forename: Fausto
authors.initials: F
authors.lastname: Petrelli
authors.affiliation: Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
authors.forename: Alberto
authors.initials: A
authors.lastname: Bottini
authors.affiliation: Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia.|Department of Pathology, University of Melbourne, Melbourne, Australia.
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Fox
authors.affiliation: Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.|Department of Medical, Surgery & Health Sciences, Università degli Studi di Trieste, Trieste, Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Generali
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068338:Everolimus / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus
keywords: everolimus; mTOR pathway; prostate cancer